While it may strike you as unseemly to seek profit from the Ebola outbreak, Nigam Arora, chief investment officer at The Arora Report, suggests considering the stock of a company that may have a positive role to play in the health crisis.
That company is OraSure Technologies.
One problem with the Ebola virus is the lack of a quick detection test for it. "OraSure is known for its rapid HIV tests, including the first in-home oral HIV test," Arora writes in an article for MarketWatch
"HIV is caused by a virus. Ebola is a virus. OraSure also has a subsidiary that is a leader in oral-fluid-sample collection. Given OraSure's capabilities in virus detection, it stands to reason that OraSure would be exploring or working on an Ebola test."
To be sure, Arora emphasizes that he has no information that OraSure is doing any such thing. "In this regard, the foregoing speculation may turn out to be entirely wrong," he writes.
So far, the company's stock hasn't gone up, unlike other companies that have any kind of connection with Ebola.
But if OraSure "is able to show progress on an Ebola test, based on the price action in the other Ebola stocks, this stock can triple or quadruple quickly."
He also cautioned that "OraSure is only a trade suitable for experienced traders; it is not an investment at this time. Only those who have experience with a strict risk control methodology should even consider this trade."
Meanwhile, beware of fraudsters claiming Ebola cures, says Colleen Tressler, a consumer education specialist at the Federal Trade Commission (FTC).
"Banking on fear, scam artists are making unsubstantiated claims that products containing everything from silver to herbal oils and snake venom can cure or prevent Ebola. Not so, says the FTC and the Food and Drug Administration," she writes on the FTC's website
© 2022 Newsmax Finance. All rights reserved.